Related Experiment Video
Updated: Oct 30, 2025
08:45
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
2.1K
Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis
Elizabeta Nemeth1, Tomas Ganz2
1Department of Medicine, University of California, Los Angeles, CA 90095, USA.
International Journal of Molecular Sciences
|July 2, 2021
Summary
The peptide hormone hepcidin regulates iron levels by interacting with ferroportin. Disruptions in this hepcidin-ferroportin interaction cause iron disorders like hereditary hemochromatosis.
Area of Science:
- Biochemistry
- Physiology
- Molecular Biology
Background:
- Iron is essential but poorly bioavailable, necessitating strict regulation in organisms.
- Vertebrates maintain iron homeostasis via the hepcidin-ferroportin axis.
- Hepcidin controls iron export by binding to ferroportin, influencing plasma iron levels.
Purpose of the Study:
- To elucidate the regulatory role of hepcidin in iron metabolism.
- To understand the mechanism of hepcidin's interaction with ferroportin (SLC40a1).
- To explore the implications of hepcidin-ferroportin dysregulation in iron-related diseases.
Main Methods:
- This study focuses on the molecular and physiological interactions between hepcidin and ferroportin.
- Analysis of genetic mutations affecting hepcidin synthesis or ferroportin binding.
- Observational studies linking hepcidin levels to iron status in various physiological and pathological conditions.
Main Results:
- Hepcidin binding to ferroportin inhibits cellular iron export, regulating plasma iron concentration.
- Decreased hepcidin levels facilitate iron release, crucial for erythropoiesis during iron deficiency or hemorrhage.
- Increased hepcidin levels restrict iron availability, acting as a host defense mechanism against pathogens.
Conclusions:
- The hepcidin-ferroportin pathway is central to maintaining iron balance and host defense.
- Dysregulation of this pathway leads to iron overload (hereditary hemochromatosis) or iron deficiency.
- Targeting the hepcidin-ferroportin interaction holds therapeutic potential for iron metabolism disorders.
More Related Videos
Related Concept Videos
01:28The Early Endosome: Endocytosis of Transferrin
4.0K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
4.0K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
43
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
43
01:21Hepatic Portal System
3.2K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
3.2K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
36
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
36
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
39
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
39
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
48
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
48